PT  - JOURNAL ARTICLE
AU  - Morobe, John Mwita
AU  - Kamau, Everlyn
AU  - Luka, Martha M.
AU  - Murunga, Nickson
AU  - Lewa, Clement
AU  - Mutunga, Martin
AU  - Bigogo, Godfrey
AU  - Otieno, Nancy
AU  - Nyawanda, Bryan
AU  - Onyango, Clayton
AU  - Nokes, D. James
AU  - Agoti, Charles N.
AU  - Munywoki, Patrick K.
TI  - Spatio-temporal distribution of rhinovirus types in Kenya: A retrospective analysis, 2014
AID  - 10.1101/2024.04.02.24305207
DP  - 2024 Jan 01
TA  - medRxiv
PG  - 2024.04.02.24305207
4099  - http://medrxiv.org/content/early/2024/04/03/2024.04.02.24305207.short
4100  - http://medrxiv.org/content/early/2024/04/03/2024.04.02.24305207.full
AB  - Rhinoviruses (RVs) are one of the most commonly detected viruses in people with acute respiratory illness (ARI). Despite their significant disease burden, RV epidemiology at national levels is underexplored. The circulation patterns of RV types throughout a population and the role of virus genotype in this distribution are ill-defined. We generated 803 VP4/VP2 gene sequences from rhinovirus-positive samples collected from ARI patients, including both in-patient and outpatient cases, between 1st January and 31st December 2014 from eleven surveillance sites across Kenya and used phylogenetics to characterise virus introductions and spread. RVs were detected throughout the year, with the highest detection rates observed from January to March and June to July. We detected a total of 114 of the 169 currently classified types. Our analysis revealed numerous virus introductions into Kenya characterized by local expansion and extinction, and extensive spatial mixing of types within the country due to the widespread transmission of the virus after an introduction. This work demonstrates that in a single year, the circulation of rhinovirus in Kenya was characterized by substantial genetic diversity, multiple introductions, and extensive geographical spread.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported by Wellcome [102975], and U.S. Centers for Disease Control and Prevention through Cooperative Agreement [#6U01GH002143].Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study was approved by the Kenya Medical Research Institute - Scientific and Ethical Review Unit (SSC #3044) and CDC Institutional Review Board (#6806) to use pre-existent, pseudonymized specimens, and data.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesSequence data generated in this study are available in GenBank under accession numbers: MZ129390 - MZ130096. Additional data and analysis scripts for this manuscript are available at the VEC Harvard Dataverse: https://doi.org/10.7910/DVN/CBHVTA